Literature DB >> 28720285

Ultrasound-Based Shear Wave Elastography in the Assessment of Patients with Diabetic Kidney Disease.

Flaviu Bob1, Iulia Grosu2, Ioan Sporea3, Simona Bota4, Alina Popescu1, Alexandra Sima5, Roxana Şirli3, Ligia Petrica1, Romulus Timar5, Adalbert Schiller1.   

Abstract

In previous studies of acoustic radiation force impulse (ARFI) elastography, using Virtual Touch tissue quantification (VTQ) (Siemens Acuson S2000), it was reported that the measurement of renal shear wave speed in patients with chronic kidney disease (CKD) is not influenced exclusively by renal fibrosis. The purpose of the present study was to analyze the role of VTQ in patients with diabetic kidney disease, considered the main cause of CKD. The study group included 164 patients: 80 patients with diabetic kidney disease (DKD) and 84 without renal disease or diabetes mellitus. In each subject in lateral decubitus, five valid VTQ measurements were performed in each kidney and a median value was calculated, the result being expressed in meters/second. The following means of the median values were obtained In DKD patients, the means of the median values were for VTQ right kidney, 2.21 ± 0.71 m/s, and for VTQ left kidney, 2.13 ± 0.72 m/s, whereas in the normal controls statistically significant higher values were obtained: 2.58 ± 0.78 m/s for VTQ right kidney (p = 0.0017) and 2.46 ± 0.81 m/s for VTQ left kidney (p = 0.006). Patients with an estimated glomerular filtration rate (eGFR) >60 mL/min (DKD stages 1 and 2 together with normal controls) had a significantly higher kidney shear wave speed compared with patients with an eGFR <60 mL/min (2.53 m/s vs. 2.09 m/s, p < 0.05). In the DKD group, there was a significant correlation between eGFR and VTQ levels for the right kidney (r = 0.28, p = 0.04). There was no correlation of VTQ values with proteinuria level, stage of diabetic retinopathy or glycated hemoglobin. Our study indicates that shear wave speed values in patients with diabetic kidney disease and eGFRs <60 mL/min are significantly lower compared with those of patients with eGFRs >60 mL/min (either normal controls or diabetic patients with DKD stages 1 and 2), and values decrease with the decrease in eGFR. However, proteinuria, diabetic retinopathy and glycated hemoglobin have no influence on VTQ.
Copyright © 2017 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetic kidney disease; Kidney shear wave speed; Virtual Touch quantification (VTQ)

Mesh:

Year:  2017        PMID: 28720285     DOI: 10.1016/j.ultrasmedbio.2017.04.019

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  5 in total

Review 1.  Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques.

Authors:  Kai Jiang; Christopher M Ferguson; Lilach O Lerman
Journal:  Transl Res       Date:  2019-04-22       Impact factor: 7.012

Review 2.  Novel Uses of Ultrasound to Assess Kidney Mechanical Properties.

Authors:  Matthew W Urban; Andrew D Rule; Thomas D Atwell; Shigao Chen
Journal:  Kidney360       Date:  2021-07-01

3.  Auto-Segmentation Ultrasound-Based Radiomics Technology to Stratify Patient With Diabetic Kidney Disease: A Multi-Center Retrospective Study.

Authors:  Jifan Chen; Peile Jin; Yue Song; Liting Feng; Jiayue Lu; Hongjian Chen; Lei Xin; Fuqiang Qiu; Zhang Cong; Jiaxin Shen; Yanan Zhao; Wen Xu; Chenxi Cai; Yan Zhou; Jinfeng Yang; Chao Zhang; Qin Chen; Xiang Jing; Pintong Huang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 4.  Kidney Ultrasound for Nephrologists: A Review.

Authors:  Rohit K Singla; Matthew Kadatz; Robert Rohling; Christopher Nguan
Journal:  Kidney Med       Date:  2022-04-07

5.  Does Early Diabetic Kidney Damage Alter Renal Elasticity? An Ultrasound-Based, Two-Dimensional Shear Wave Elastography Study.

Authors:  Nesrin Gunduz; Aysenur Buz; Adnan Kabaalioglu
Journal:  Medeni Med J       Date:  2021-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.